美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

减肥药

1,239.23

-16.4763-1.31%

涨家数：1

跌家数：5

平家数：1

市盈率：- -

高：1,268.38

开：1,255.98

低：1,236.42

收：1,255.70

数据加载中...

超卖信号显现！利空因素逐步出清，诺和诺德跌出“深度价值”？

新闻摘要-英国商业》--6 月 23 日

1.8亿美元首付款到了:国内药企，竞争力十足

生物药大时代

本周解锁数据一览：BLAST、VENOM、SOON将迎一次性大额解锁

要抢诺和诺德饭碗？这款国产减肥药太猛了

阿尔法工场研究院

诺和诺德实验性减肥药数据显示副作用大多轻微

环球市场播报

2025年ADA大会进行时：全球创新类代谢药物同台竞技长效、口服、多靶点及减脂不减肌成突围重点

多项减重药研发成果亮相ADA大会国产药数据比肩跨国同行

诺和诺德(NVO.US)表示早期试验的全部结果显示该公司的实验性药物Amycretin可以帮助超重和肥胖的成年人减掉高达

股价腰斩后，诺和诺德迎来翻盘希望？实验数据显示新药减重效果击败Zepbound

华尔街见闻

辉瑞6月20日成交额为15.10亿美元

超60亿美元“扫货”中国创新药，辉瑞能赚多少钱？

诺和诺德6月20日成交额为6.05亿美元

6月21日据诺和诺德网站消息在芝加哥举行的美国糖尿病协会（ADA）科学会议上诺和诺德公布了针对非糖尿病肥胖症患者的3b期

ADA会议上演减肥药“华山论剑”，诺礼安进同台交锋

【减重24.3%！诺和诺德(NVO.US)新一代减肥药Amycretin小型试验取得积极成果】智通财经APP获悉，诺和诺

安进6月20日成交额为19.74亿美元

诺和诺德减肥药早期试验结果显著

诺和诺德发布降糖药Amycretin临床试验的早期结果。Amycretin表现出改善血糖水平的迹象。Amycretin在

Altimmune, Inc.盘中异动下午盘股价大涨5.09%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK4599/news?page=5"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"减肥药","latestPrice":1239.2252,"timestamp":1751054399999,"preClose":1255.7015,"halted":0,"volume":78911461,"delay":0,"changeRate":-0.013121,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-16.476318,"latestTime":"06-27 16:00:00 EDT","open":1255.9792,"high":1268.3782,"low":1236.4158,"amount":5613144157.869724,"amplitude":0.025454,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":9.605108,"peRate":31.853461,"turnoverRate":0.007458,"increases":1,"decrements":5,"flats":1,"marketCap":1330059827968,"floatMarketCap":1241837252832},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1268.3782,"amplitude":0.025454,"preClose":1255.7015,"low":1236.4158,"pbRate":"9.605108","latestPrice":1239.2252,"volume":78911461,"delay":0,"open":1255.9792,"prevYearClose":1305.0607,"prevWeekClose":1250.9895,"prevMonthClose":1216.6,"prevQuarterClose":1314.3724,"fiveDayClose":1250.9895,"twentyDayClose":1193.2659,"sixtyDayClose":1283.6255,"secType":"PLATE","market":"US","turnoverRate":0.007458,"peRate":31.853461,"marketCap":1330059827968,"floatMarketCap":1241837252832,"timestamp":1751054399999,"nameCN":"减肥药"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":1,"down":5,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2545546044","title":"超卖信号显现！利空因素逐步出清，诺和诺德跌出“深度价值”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2545546044","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545546044?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 15:35","pubTimestamp":1750664120,"startTime":"0","endTime":"0","summary":"诺和诺德股价终于在经历了从 2024 年 6 月峰值的痛苦下跌后触底反弹，这是因为 GLP-1药物方面的不利因素有所缓解。诺和诺德超卖状态预示着巨大的上涨潜力，因不利因素减弱目前，诺和诺德股价较去年创下新高的水平激进腰斩，经过大幅下跌后，诺和诺德市盈率低于 10 年均值，且低于行业平均的水平与主要竞争对手。这些原因正是诺和诺德公司极低估值具有重大投资价值的原因。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308341.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"超卖信号显现！利空因素逐步出清，诺和诺德跌出“深度价值”？","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4532","BK4599","LU0154236417.USD","LU1093756325.SGD","NVO","BK4007","IE00BKVL7J92.USD","BK4588"],"gpt_icon":0},{"id":"2545646878","title":"新闻摘要-英国商业》--6 月 23 日","url":"https://stock-news.laohu8.com/highlight/detail?id=2545646878","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545646878?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 10:35","pubTimestamp":1750646109,"startTime":"0","endTime":"0","summary":"新闻摘要-英国商业》--6 月 23 日路透6月23日 - 以下是英国报纸商业版的热门新闻。电讯报 - 在美国于周日凌晨空袭伊朗之后，英国航空公司和新加坡航空公司SIAL.SI暂停了  飞往迪拜的航班。天空新闻 - 英国商务大臣乔纳森-雷诺兹表示， ，伊朗对英国的威胁已经达到了 \"相当高的水平\"，而且在美国打击伊朗核基地之后可能会增加。- 据报道，上周在大使馆附近的抗议活动中发生斗殴事件后，伦敦警方称已指控  七名伊朗人严重伤害他人身体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nL4S3SQ05Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","LU0266013472.USD","LU0289739699.SGD","LU1069344957.HKD","LU1720051017.SGD","LU0889565916.HKD","LU0238689110.USD","SGXZ57979304.SGD","SG9999015986.USD","BK6523","LU0456855351.SGD","IE00BJLML261.HKD","LU0672654240.SGD","LU1366192091.USD","LU1291159041.SGD","SG9999018857.SGD","SG9999001176.USD","LU0114720955.EUR","LU1623119135.USD","LU2471134879.HKD","LU2750360997.AUD","SG9999018865.SGD","SG9999017495.SGD","LU2471134523.USD","LU2237443895.HKD","BK4599","SG9999013486.USD","LU1720051108.HKD","LU1868836914.USD","LU2552382058.USD","LU1127390331.HKD","LU0943347566.SGD","SGXZ58947870.SGD","SGXZ81514606.USD","LU2750360641.GBP","IE00B2B36J28.USD","LU0354030511.USD","LU2236285917.USD","LU2324357040.USD","LU1989771016.USD","LU2237438978.USD","SG9999014914.USD","LU2456880835.USD","LU0006306889.USD","LU0882574055.USD","IE00BK4W5M84.HKD","LU2552382132.HKD","LU0417517546.SGD","LU2237443978.SGD"],"gpt_icon":1},{"id":"2545636944","title":"1.8亿美元首付款到了:国内药企，竞争力十足","url":"https://stock-news.laohu8.com/highlight/detail?id=2545636944","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545636944?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 10:23","pubTimestamp":1750645418,"startTime":"0","endTime":"0","summary":"根据独家许可协议并受其条款和条件约束，联邦生物将获得诺和诺德支付的2亿美元的首付款（税前），最高达18亿美元的潜在里程碑付款，以及在中国内地（大陆）、香港特别行政区、澳门特别行政区和台湾地区外基于净销售额的分级特许权使用费。今天，6月20日：收到来自诺和诺德的1.8亿美元首付款。动作迅速，三个月完成交割。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623103606a717ebbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623103606a717ebbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4532","LU1093756325.SGD","BK4599","BK4588","IE00BZ1G4Q59.USD","NVO","LU0154236417.USD","IE00BKVL7J92.USD","LU1093756168.USD","BK4007"],"gpt_icon":1},{"id":"2545452365","title":"本周解锁数据一览：BLAST、VENOM、SOON将迎一次性大额解锁","url":"https://stock-news.laohu8.com/highlight/detail?id=2545452365","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545452365?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 09:06","pubTimestamp":1750640760,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//flash/299501","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_zh_live","symbols":["BK4179","US30Y.BOND","US5Y.BOND","AGIX","US10Y.BOND","VELO","US12M.BOND","FET","US3Y.BOND","BK4599","US2Y.BOND","US7Y.BOND","BK4139","LU1878469433.USD","US6M.BOND","ALT"],"gpt_icon":0},{"id":"2545560644","title":"要抢诺和诺德饭碗？这款国产减肥药太猛了","url":"https://stock-news.laohu8.com/highlight/detail?id=2545560644","media":"阿尔法工场研究院","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545560644?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 07:01","pubTimestamp":1750633313,"startTime":"0","endTime":"0","summary":"艾可鲁肽是一种每周注射一次的药物，目前正接受中国监管机构审查，用于治疗肥胖和糖尿病。潘海表示，该药物最早有望在2026年初获得批准。相比之下，诺和诺德的Wegovy和礼来的Zepbound在中国的临床试验中，这一比例为85%-87%。竞争态势还将进一步加剧。在海外，赛湾已在澳大利亚和新西兰开展了艾可鲁肽的临床研究，并与韩国达成了商业化协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623070537a717a9db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623070537a717a9db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","LU1093756168.USD","NVO","BK4585","BK4007","BK4588","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0154236417.USD","LU1093756325.SGD","BK4532"],"gpt_icon":1},{"id":"2545945833","title":"诺和诺德实验性减肥药数据显示副作用大多轻微","url":"https://stock-news.laohu8.com/highlight/detail?id=2545945833","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545945833?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 00:42","pubTimestamp":1750610520,"startTime":"0","endTime":"0","summary":"诺和诺德周日表示，其实验性减肥药 CagriSema 两项后期试验的完整结果显示，副作用主要为轻度至中度，且包括血糖水平在内的其他疗效结果均呈阳性。　　该公司此前已公布这两项为期 68 周研究的主要结果，发现 CagriSema 可使超重或肥胖成年人减重近 23%，超重 2 型糖尿病患者减重近 16%。但这些结果令投资者失望，导致诺和诺德股价下跌。严重不良事件发生率在 CagriSema 组为 9.8%，安慰剂组为 6.1%。　　诺和诺德表示，计划在 2026 年第一季度提交 CagriSema 的监管批准申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-06-23/doc-infayqcw1252460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0154236417.USD","BK4532","IE00BKVL7J92.USD","BK4599","LU1093756325.SGD","BK4585","BK4007","NVO","BK4588","IE00BZ1G4Q59.USD","LU1093756168.USD"],"gpt_icon":1},{"id":"2545543289","title":"2025年ADA大会进行时：全球创新类代谢药物同台竞技 长效、口服、多靶点及减脂不减肌成突围重点","url":"https://stock-news.laohu8.com/highlight/detail?id=2545543289","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545543289?lang=zh_cn&edition=fundamental","pubTime":"2025-06-22 19:45","pubTimestamp":1750592700,"startTime":"0","endTime":"0","summary":"在6月20日至23日举行的第85届美国糖尿病协会大会上，来自全球药企的创新类代谢药物再度同台竞技。随着ADA摘要全文基本公布，多款创新减肥药物的减重数据浮出水面。礼来则公布了口服小分子GLP-1RA药物Orforglipron 3期研究结果。最高剂量组患者平均减重达7.3kg。长效、口服、多靶点及减脂不减肌成减重药物突围点在ADA大会上，一些基于创新机制的减肥药物引发关注。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2025-06-22/doc-infaycpy3795026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BKVL7J92.USD","BK4599","LU0154236417.USD","LU1093756325.SGD","LU1093756168.USD","NVO","BK4588","IE00BZ1G4Q59.USD","BK4585","BK4532","BK4007"],"gpt_icon":1},{"id":"2545439843","title":"多项减重药研发成果亮相ADA大会 国产药数据比肩跨国同行","url":"https://stock-news.laohu8.com/highlight/detail?id=2545439843","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545439843?lang=zh_cn&edition=fundamental","pubTime":"2025-06-22 15:32","pubTimestamp":1750577552,"startTime":"0","endTime":"0","summary":"【多项减重药研发成果亮相ADA大会 国产药数据比肩跨国同行】在美国当地时间6月20日至23日举行的美国糖尿病协会（ADA）科学年会上，来自礼来、诺和诺德等跨国厂商以及中国制药公司的多项GLP-1减重药最新临床数据公布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202506223436972497.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202506223436972497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","LU1093756325.SGD","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4585","BK4532","BK4599","BK4007","LU1093756168.USD","NVO","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2545486594","title":"诺和诺德(NVO.US)表示早期试验的全部结果显示该公司的实验性药物Amycretin可以帮助超重和肥胖的成年人减掉高达","url":"https://stock-news.laohu8.com/highlight/detail?id=2545486594","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545486594?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 20:27","pubTimestamp":1750508835,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"29069a2d258c3012955fca2e6ff29131","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","LU1093756325.SGD","NVO","IE00BZ1G4Q59.USD","BK4532","BK4599","BK4588","IE00BKVL7J92.USD","BK4585","LU1093756168.USD","LU0154236417.USD"],"gpt_icon":0},{"id":"2545648375","title":"股价腰斩后，诺和诺德迎来翻盘希望？实验数据显示新药减重效果击败Zepbound","url":"https://stock-news.laohu8.com/highlight/detail?id=2545648375","media":"华尔街见闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545648375?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 18:09","pubTimestamp":1750500548,"startTime":"0","endTime":"0","summary":"减肥药竞争白热化下，诺和诺德迎来关键突破。据《柳叶刀》医学期刊周六发布的试验数据，诺和诺德新药amycretin注射剂最高剂量治疗的参与者平均减重24.3%，这一结果超过了目前市场上最成功的减重药物——礼来的Zepbound（平均减重22.5%）和Novo的Wegovy（平均减重15%）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3749566","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"29069a2d258c3012955fca2e6ff29131","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3749566","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4599","IE00BKVL7J92.USD","LU0154236417.USD","BK4007","BK4588","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","LU1093756325.SGD","BK4585"],"gpt_icon":1},{"id":"2545107339","title":"辉瑞6月20日成交额为15.10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545107339","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545107339?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 12:45","pubTimestamp":1750481152,"startTime":"0","endTime":"0","summary":"美东时间2025年6月20日，辉瑞成交额为15.10亿美元，成交额较昨日增加70.30%，当日成交量为6309.81万股。辉瑞于2025年6月20日涨0.38%，报23.97美元，该股过去5个交易日跌3.5%，年初至今跌6.4%，过去60日跌4.4%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-20|15.10亿|70.30%|6309.81万|#|2025-06-18|8.87亿|-8.92%|3707.62万|#|2025-06-17|9.74亿|13.70%|4040.88万|#|2025-06-16|8.56亿|-25.20%|3510.21万|#|2025-06-13|11.45亿|8.78%|4636.84万|辉瑞是全球最大的制药公司之一，年销售额接近500亿美元。辉瑞在全球销售这些产品，国际销售额占其总销售额的近50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621124600a715a010&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621124600a715a010&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1894683264.USD","LU0306807586.USD","IE00B19Z3B42.SGD","BK4550","BK4534","SGXZ57979304.SGD","BK4533","LU0456855351.SGD","LU0321505868.SGD","LU0289739699.SGD","LU0985481810.HKD","LU0058720904.USD","LU1023059063.AUD","IE00BLSP4452.SGD","LU0225284248.USD","IE000M9KFDE8.USD","SG9999011175.SGD","BK4581","LU0321505439.SGD","SG9999002232.USD","LU0170899867.USD","LU1066051498.USD","LU1894683348.USD","LU1066053197.SGD","PFE","SG9999001176.USD","BK4007","SG9999013999.USD","IE00BBT3K403.USD","LU0122379950.USD","IE00BLSP4239.USD","BK4588","LU1883839398.USD","BK4592","LU0234572021.USD","IE0002270589.USD","SG9999002224.SGD","SG9999003800.SGD","BK4599","BK4585","SG9999001176.SGD","LU1057294990.SGD","LU0868494617.USD","BK4568","LU0225771236.USD","IE00B19Z3581.USD","LU0306806265.USD"],"gpt_icon":0},{"id":"2545310220","title":"超60亿美元“扫货”中国创新药，辉瑞能赚多少钱？","url":"https://stock-news.laohu8.com/highlight/detail?id=2545310220","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545310220?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 12:33","pubTimestamp":1750480417,"startTime":"0","endTime":"0","summary":"中新经纬6月21日电 近期，三生制药将原研药SSGJ-707授权给跨国医药企业辉瑞，辉瑞将向三生制药支付首付款12.5亿美元，叠加里程碑付款交易总额高达60.5亿美元。这一金额打破中国医药企业海外授权金额首付款纪录。礼新医药将获得5.88亿美元的首付款以及最高27亿美元的里程碑付款。根据研究型数据统计平台Statista，截至2022年底，立普妥的终身销售额总计为1720亿美元，预计到2028年将再增加约60亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621123600a7159d72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621123600a7159d72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4534","LU1883839398.USD","BK4588","LU0306806265.USD","LU1066051498.USD","SGXZ57979304.SGD","LU0234572021.USD","LU0225284248.USD","BK4568","BK4592","BK4550","PFE","IE00B19Z3581.USD","IE00BLSP4452.SGD","SG9999002224.SGD","LU0306807586.USD","BK4585","IE00BBT3K403.USD","LU0868494617.USD","LU1057294990.SGD","SG9999001176.SGD","IE00B19Z3B42.SGD","LU1894683348.USD","LU0170899867.USD","IE000M9KFDE8.USD","BK4599","BK4533","LU1023059063.AUD","LU1894683264.USD","BK4581","LU0122379950.USD","LU0225771236.USD","LU0985481810.HKD","LU1066053197.SGD","SG9999003800.SGD","BK4007","SG9999002232.USD","LU0456855351.SGD","IE0002270589.USD","SG9999001176.USD","SG9999013999.USD","LU0289739699.SGD","LU0321505868.SGD","LU0058720904.USD","LU0321505439.SGD","IE00BLSP4239.USD","SG9999011175.SGD"],"gpt_icon":0},{"id":"2545102453","title":"诺和诺德6月20日成交额为6.05亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545102453","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545102453?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 12:20","pubTimestamp":1750479626,"startTime":"0","endTime":"0","summary":"美东时间2025年6月20日，诺和诺德成交额为6.05亿美元，成交额较昨日增加48.97%，当日成交量为821.30万股。诺和诺德于2025年6月20日跌0.32%，报73.77美元，该股过去5个交易日跌8.98%，年初至今跌13.09%，过去60日涨1.81%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621122029a4b5b6bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621122029a4b5b6bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","LU0154236417.USD","BK4532","BK4007","LU1093756325.SGD","IE00BKVL7J92.USD","NVO","IE00BZ1G4Q59.USD","BK4588","BK4585","LU1093756168.USD"],"gpt_icon":1},{"id":"2545102809","title":"6月21日据诺和诺德网站消息在芝加哥举行的美国糖尿病协会（ADA）科学会议上诺和诺德公布了针对非糖尿病肥胖症患者的3b期","url":"https://stock-news.laohu8.com/highlight/detail?id=2545102809","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545102809?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 11:49","pubTimestamp":1750477746,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1093756168.USD","BK4585","BK4532","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4007","BK4599","BK4588","IE00BKVL7J92.USD","LU0154236417.USD","NVO"],"gpt_icon":0},{"id":"2545310418","title":"ADA会议上演减肥药“华山论剑”，诺礼安进同台交锋","url":"https://stock-news.laohu8.com/highlight/detail?id=2545310418","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545310418?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 10:59","pubTimestamp":1750474743,"startTime":"0","endTime":"0","summary":"礼来将于 6 月 21 日在由ADA主办的研讨会上公布其针对 2 型糖尿病成年患者的在研口服减肥疗法的 3 期临床试验结果。与此同时，安进的实验性减肥疗法MariTide的安全性将成为关注焦点。该试验招募的对象为患有肥胖症或超重症但未患有 2 型糖尿病的个体。此前，Cantor Fitzgerald的一份报告指出，骨矿物质密度的潜在下降可能是MariTide 产品所带来的一种安全隐患。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B4R5TH58.HKD","LU2242646821.SGD","BK4533","BK4599","IE00BJT1NW94.SGD","LU2112291526.USD","LU0122379950.USD","BK4139","LU0058720904.USD","LU0889565916.HKD","LU0289739699.SGD","AMGN","BK4581","LU1057294990.SGD","BK4534","IE00BJJMRZ35.SGD","LU2089984988.USD","LU0868494617.USD","LU1983299246.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU1571399168.USD","IE0002141913.USD","LU2468319806.SGD","SG9999001440.SGD","LU2242652126.USD","BK4585","IE00B2B36J28.USD","LU0320765992.SGD","BK4588","LU1023059063.AUD","IE0009355771.USD","BK4566","LU0109394709.USD"],"gpt_icon":0},{"id":"2545018111","title":"【减重24.3%！诺和诺德(NVO.US)新一代减肥药Amycretin小型试验取得积极成果】智通财经APP获悉，诺和诺","url":"https://stock-news.laohu8.com/highlight/detail?id=2545018111","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545018111?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 09:38","pubTimestamp":1750469891,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"29069a2d258c3012955fca2e6ff29131","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BKVL7J92.USD","BK4007","LU0154236417.USD","BK4588","LU1093756168.USD","BK4532","NVO","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4585","BK4599"],"gpt_icon":0},{"id":"2545109910","title":"安进6月20日成交额为19.74亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545109910","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545109910?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 09:16","pubTimestamp":1750468579,"startTime":"0","endTime":"0","summary":"美东时间2025年6月20日，安进成交额为19.74亿美元，成交额较昨日增加236.13%，当日成交量为680.14万股。安进于2025年6月20日跌0.1%，报289.33美元，该股过去5个交易日跌2.68%，年初至今涨12.9%，过去60日跌4.88%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621091633a4b586cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621091633a4b586cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999001440.SGD","LU0058720904.USD","LU1983299246.USD","AMGN","BK4588","LU0109394709.USD","BK4534","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4585","LU1057294990.SGD","IE00B2B36J28.USD","LU0320765992.SGD","LU1061106388.HKD","BK4566","BK4581","LU1023059063.AUD","BK4139","LU0868494617.USD","LU0289739699.SGD","LU2089984988.USD","IE0002141913.USD","LU2468319806.SGD","LU2242652126.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU1571399168.USD","BK4533","LU0889565916.HKD","BK4599","LU2112291526.USD","LU0122379950.USD","LU2242646821.SGD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2545210527","title":"诺和诺德减肥药早期试验结果显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2545210527","media":"DoNews","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545210527?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 07:43","pubTimestamp":1750462983,"startTime":"0","endTime":"0","summary":"6月21日，诺和诺德公司发布减肥药Amycretin早期试验数据。结果显示，在36周内，受试者平均体重下降24.3%，同时药物还显示出改善血糖水平的潜力。这一进展可能为肥胖及糖尿病患者提供新治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506210744159525494f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"29069a2d258c3012955fca2e6ff29131","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506210744159525494f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","IE00BZ1G4Q59.USD","LU1093756325.SGD","LU1093756168.USD","LU0154236417.USD","BK4532","BK4585","BK4588","BK4599","IE00BKVL7J92.USD","BK4007"],"gpt_icon":0},{"id":"2545510523","title":"诺和诺德发布降糖药Amycretin临床试验的早期结果。Amycretin表现出改善血糖水平的迹象。Amycretin在","url":"https://stock-news.laohu8.com/highlight/detail?id=2545510523","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545510523?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 07:33","pubTimestamp":1750462385,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0154236417.USD","IE00BKVL7J92.USD","BK4585","BK1576","LU1093756168.USD","BK4588","BK1141","BK4599","BK4007","03347","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4532","BK1583","NVO"],"gpt_icon":0},{"id":"2545678172","title":"Altimmune, Inc.盘中异动 下午盘股价大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2545678172","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545678172?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 02:19","pubTimestamp":1750443594,"startTime":"0","endTime":"0","summary":"北京时间2025年06月21日02时19分，Altimmune, Inc.股票出现异动，股价快速上涨5.09%。Altimmune, Inc.股票所在的生物技术行业中，整体跌幅为0.48%。其相关个股中，Immatics N V C/Wts 01/07/2025 、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Processa Pharmaceuticals, Inc.涨幅较大，Nucana Plc、Processa Pharmaceuticals, Inc.、Aptevo Therapeutics Inc.较为活跃，换手率分别为1643.15%、1137.12%、427.06%，振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Galectin Therapeutics Inc.、Seastar Medical Holding Corporation，振幅分别为65.00%、62.42%、52.25%。Altimmune, Inc.公司简介：Altimmune Inc 是一家处于临床阶段的生物制药公司，专注于开发针对肥胖症、代谢性疾病和肝脏疾病的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621021955978844e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621021955978844e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALT","BK4139","BK4599","LU1878469433.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":5,"totalSize":163,"code":"91000000","status":"200"}]}}